- Home
- WSFS vs DNLI Comparison
WSFS vs DNLI Comparison
Compare WSFS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSFS
- DNLI
- Stock Information
- Founded
- WSFS 1980
- DNLI 2013
- Country
- WSFS United States
- DNLI United States
- Employees
- WSFS N/A
- DNLI N/A
- Industry
- WSFS Major Banks
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSFS Finance
- DNLI Health Care
- Exchange
- WSFS Nasdaq
- DNLI Nasdaq
- Market Cap
- WSFS 3.0B
- DNLI 3.3B
- IPO Year
- WSFS N/A
- DNLI 2017
- Fundamental
- Price
- WSFS $57.14
- DNLI $23.04
- Analyst Decision
- WSFS Buy
- DNLI Strong Buy
- Analyst Count
- WSFS 4
- DNLI 11
- Target Price
- WSFS $59.00
- DNLI $40.40
- AVG Volume (30 Days)
- WSFS 272.8K
- DNLI 784.6K
- Earning Date
- WSFS 01-23-2025
- DNLI 11-06-2024
- Dividend Yield
- WSFS 1.05%
- DNLI N/A
- EPS Growth
- WSFS N/A
- DNLI N/A
- EPS
- WSFS 4.39
- DNLI N/A
- Revenue
- WSFS $971,986,000.00
- DNLI N/A
- Revenue This Year
- WSFS N/A
- DNLI N/A
- Revenue Next Year
- WSFS N/A
- DNLI $420.35
- P/E Ratio
- WSFS $12.97
- DNLI N/A
- Revenue Growth
- WSFS 4.32
- DNLI 204.74
- 52 Week Low
- WSFS $40.20
- DNLI $14.56
- 52 Week High
- WSFS $62.75
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- WSFS 45.53
- DNLI 37.02
- Support Level
- WSFS $56.43
- DNLI $22.77
- Resistance Level
- WSFS $58.41
- DNLI $24.15
- Average True Range (ATR)
- WSFS 1.21
- DNLI 0.96
- MACD
- WSFS -0.60
- DNLI -0.05
- Stochastic Oscillator
- WSFS 9.42
- DNLI 7.84
About WSFS WSFS Financial Corporation
WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.